Evidence map›Paper›PMID 23576410›Full record

ReviewJournal of child neurology2013

Aiming at neuroblastoma and hitting other worthy targets.

Nina F Schor

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of child neurology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Nina F SchorDepartment of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA. nina_schor@urmc.rochester.edu
University of Rochester · US

Funding

NEUROTROPHIC MECHANISMS IN NEUROBLASTOMAR01NS038569 · NINDS · UNIVERSITY OF ROCHESTER · PI SCHOR, NINA F · 2000 to 2008
$2.4M
TARGETED THERAPY FOR CHEMORESISTANT TUMORSR01CA074289 · NCI · UNIVERSITY OF ROCHESTER · PI SCHOR, NINA F · 1998 to 2006
$1.6M
Antioxidant Strategies for Parkinson's DiseaseR01NS041297 · NINDS · UNIVERSITY OF ROCHESTER · PI SCHOR, NINA F · 2002 to 2005
$1.2M
NCI NIH HHS R01 CA074289NCI NIH HHS R01-CA074289NINDS NIH HHS R01 NS038569NINDS NIH HHS R01-NS038569NINDS NIH HHS R01 NS041297NINDS NIH HHS R01-NS041297
6 · The paper itself

Abstract

Neuroblastoma is, at once, the most common and deadly extracranial solid tumor of childhood. Efforts aimed at targeting the neural characteristics of these tumors have taught us much about neural crest cell biology, apoptosis induction in the nervous system, and neurotrophin receptor signaling and intracellular processing. But neuroblastoma remains a formidable enemy to the oncologist and an enigmatic target to the neuroscientist.

Indexed as

AnimalsAntineoplastic AgentsApoptosisChildDrug DiscoveryHumansMolecular Targeted TherapyNeural CrestNeuroblastomaPrecision MedicineReceptors, Nerve Growth FactorSignal TransductionAntineoplastic AgentsReceptors, Nerve Growth Factorapoptosisneural crest tumorsneurotrophin receptors

Identifiers

PMID23576410
PMCPMC11770395
OpenAlexW2039286348

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.